Core Viewpoint - Huasheng Technology (SZ000790) has received an administrative regulatory decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, leading to a requirement for corrective measures and warnings issued to key executives [2][4][5]. Group 1: Accounting Issues - The company has been found to have irregular accounting practices, including misclassification of advertising expenses as intangible assets by its subsidiary Hainan Rongsheng Hong Technology Co., Ltd. in 2021 [2]. - In 2023, another subsidiary, Tibet Kangyu Pharmaceutical Co., Ltd., recognized revenue from medical device sales without actual transfer of control to customers, leading to subsequent returns [2]. - Additionally, sales expenses from Chengdu Yuanhong Mineral Water Co., Ltd. were incorrectly accounted for in other subsidiaries, affecting performance assessment accuracy [2]. Group 2: Non-operational Fund Occupation - In 2021, Hainan Huasheng Development Holding Co., Ltd., a subsidiary, prepaid non-main business contract funds, which were later returned after five months, during which some funds flowed into companies controlled by the actual controller, constituting non-operational fund occupation [3]. Group 3: Internal Control Deficiencies - The internal control systems of the subsidiaries are inadequate, with issues such as improper expense reimbursement documentation and non-compliance with procurement management protocols [3]. - The company lacks a robust internal control system for large non-main business expenditures, leading to non-operational fund occupation in 2021 [3]. Group 4: Executive Accountability - Key executives, including Huang Mingliang (Chairman and President), Li Jun (Vice President and CFO), and Song Gang (Vice President), have been held responsible for the identified accounting and internal control issues [4][5]. Group 5: Company Performance - In 2024, Huasheng Technology reported revenue of 864 million yuan, a year-on-year decrease of 13.89%, and a net profit attributable to shareholders of -6.69 million yuan, down 124.19% [8]. - In the first quarter of 2025, the company achieved revenue of 127 million yuan, a decline of 29.21%, with a net profit of -14.59 million yuan, a drop of 740.09% year-on-year [9].

Group 1 - Sanofi's innovative drug company, Sangfor, has granted Pfizer exclusive global rights (excluding mainland China) for the development, production, and commercialization of the PD-1/VEGF bispecific antibody SSGJ-707, marking a significant milestone for domestic pharmaceutical companies in entering the global market [1] - Pfizer will pay a non-refundable and non-offsettable upfront payment of $1.25 billion, with potential milestone payments reaching up to $4.8 billion based on development, regulatory approval, and sales, along with a double-digit percentage sales revenue share based on product sales in authorized regions [1] Group 2 - Yipinhong announced the acquisition of a 15.25% stake in its subsidiary Guangzhou Rui'an Bo from minority shareholder Arthrosi for $6.8 million (approximately 49 million RMB) to enhance its market rights for the innovative drug AR882 in China and to promote efficient research and rapid market entry [2] - The transaction's pricing and the ongoing technical support from Arthrosi will be closely monitored for future clinical progress and market access efficiency [2] Group 3 - Huasheng Technology received an administrative regulatory measure from the Sichuan Securities Regulatory Bureau, which ordered the company to rectify issues related to accounting irregularities, non-operating fund occupation, and inadequate internal controls [3] - The regulatory action highlights weaknesses in the company's governance structure and compliance awareness, potentially affecting the rights of minority investors [3] Group 4 - Fosun Pharma announced the resignation of Rong Yang, CEO of its U.S. subsidiary, due to personal reasons, raising concerns about the continuity of leadership and strategic direction in the critical U.S. market for innovative drug commercialization [4] - The company is currently expanding its capabilities in the U.S. for both generic and innovative drug registration and commercialization [4]

Core Viewpoint - Chengdu Huasheng Technology Group Co., Ltd. received an administrative supervision decision from the Sichuan Securities Regulatory Bureau due to various accounting and internal control issues, which require corrective actions and warnings for responsible individuals [1][2][3]. Group 1: Administrative Supervision Measures - The company was found to have incorrectly recorded intangible assets and recognized revenue from medical device sales without actual transfer of control to customers, leading to issues with revenue recognition [1][2]. - There were instances of non-operating fund occupation and failure to disclose related party transactions with the actual controller, which violated internal control regulations [2][3]. - The responsible individuals, including the chairman and other executives, received warning letters for their lack of diligence in addressing these issues [3]. Group 2: Required Actions and Compliance - The company is required to conduct a thorough review of its financial accounting, fund usage, and internal control weaknesses, and to implement effective measures for rectification [3][4]. - A written report detailing corrective measures must be submitted to the regulatory authority within 30 days of receiving the decision [3][4]. - The company emphasized its commitment to improving compliance with laws and regulations, enhancing operational standards, and maintaining the interests of shareholders [4][5].

1.会计核算不规范。一是2021年子公司海南融盛弘科技有限公司将部分广告费用支出 错误计入无形资产。二是2023年子公司西藏康域药业有限公司(以下简称西藏康域)部分医 疗器械销售，在未发生实物流转，控制权未转移给客户的情况下即确认收入，且发生期后 退货。三是2023年子公司成都远泓矿泉水有限公司(存在业绩承诺)少量销售费用核算至其 他子公司，影响业绩考核测算精准性。上述情形不符合《企业会计准则第6号——无形资产》 第十二条第二款、《企业会计准则第14号——收入》第十三条第一款第三项及第四项、《企 业会计准则——基本准则》第五条相关规定。 证券代码：000790 证券简称：华神科技 公告编号：2025-019 成都华神科技集团股份有限公司 关于收到中国证券监督管理委员会四川监管局 行政监管措施决定书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 成都华神科技集团股份有限公司（以下简称"公司"）及相关责任人于近日收到中国证 券监督管理委员会四川监管局（以下简称"四川证监局"）出具的《关于对成都华神科技集 团股份有限公司采取责令改正并对黄明良等相关责任人采取 ...

Core Viewpoint - The company is facing challenges in its financial performance for 2024, with a significant decline in revenue and net profit, primarily due to strategic business adjustments and ongoing project developments [2]. Group 1: Financial Performance - In 2024, the company's operating revenue decreased by 13.89% year-on-year, resulting in a net profit loss [2]. - The decline in revenue and profit is attributed to the active contraction of the construction steel structure business, the ongoing trial production of the Shandong Lingkai project, and increased financial costs due to higher bank financing [2]. Group 2: Market Position and Competitive Advantage - The company has a strong market competitiveness and brand recognition in the pharmaceutical and health beverage sectors, with several products included in the medical insurance catalog [3]. - The company's health business segment, Huashen Blue Light, possesses rare mineral water resources, with its Biri 59 product having a silicate content of 59.99 mg/L, significantly exceeding national standards [3]. Group 3: Research and Development Focus - The company plans to focus on the in-depth exploration and secondary development of major traditional Chinese medicine products, particularly the Sanqi Tongshu capsules and Biyuan Shu, to enhance product application range and efficacy [4]. Group 4: Response to Industry Policy Changes - The company is closely monitoring changes in medical insurance payment reforms and drug procurement policies, aiming to enhance its risk resistance through market expansion and product quality management [5]. Group 5: New Market Expansion - The company is considering international market expansion based on its core traditional Chinese medicine products, which are recognized in the German Pharmacopoeia, while also planning to develop related health products and services [6]. Group 6: Asset Restructuring and Strategic Investment - The company will prudently evaluate asset restructuring and strategic investment opportunities based on its development strategy and market conditions [7].

Group 1: Financial Performance - In 2024, the company's operating revenue decreased by 13.89%, resulting in a net loss due to intensified market competition and rising costs [3] - The decline in revenue and profit was primarily due to the contraction of the construction steel structure business and the ongoing trial production phase of the Shandong Lingkai project, which has not yet generated sales [3] Group 2: Market Position and Competitive Advantage - The company has a strong market presence in the pharmaceutical and health beverage sectors, with key products like Sanqi Tongshu Capsules and Biyuan Shu Oral Liquid included in the National Basic Medical Insurance Catalog [3] - The company ranks first in Chengdu's bottled drinking water market, leveraging unique mineral resources that enhance its product offerings [3] Group 3: Research and Development Focus - Future R&D efforts will concentrate on deepening the development of major traditional Chinese medicine products, particularly those with significant market influence [4] - The company aims to enhance product application range and efficacy stability through quality standard improvements [4] Group 4: Response to Industry Changes - The company is closely monitoring industry policy changes, such as medical insurance payment reforms, to ensure stable business development [4] - Strategies include expanding outpatient market channels and enhancing product quality management to mitigate policy risks [4] Group 5: Future Growth Strategies - The company is considering international market expansion based on strategic planning and market conditions, particularly for its core traditional Chinese medicine products [4] - Plans to extend the product line and develop related health products to meet diverse customer needs are in place [4]

Group 1 - Yitong Century won a bid for a communication engineering construction service project from China Mobile, with a total bid amount of 228 million yuan (including tax) [1] - Zhiyuan New Energy plans to repurchase shares worth between 33 million and 66 million yuan, with a maximum repurchase price of 22.00 yuan per share [1] - GAC Group reported April automobile sales of 116,400 units, a year-on-year decrease of 12.66% [2] - JAC Motors reported April automobile sales of 30,764 units, a year-on-year decrease of 3.55% [3] Group 2 - Fosun Pharma's subsidiary received FDA approval for a clinical trial of a live biotherapeutic product aimed at treating androgenetic alopecia [4] - Liangxin Co. obtained multiple patent certificates, including 2 invention patents and 32 utility model patents [5] - Sainuo Medical's two products received medical device registration certificates in Mexico and Ecuador [5] - Huayu Pharmaceutical's two products received marketing approvals in France and Spain [6] Group 3 - Shengnong Development reported April sales revenue of 1.533 billion yuan, a year-on-year increase of 0.68% [6] - Hasi Lian's potassium chloride and sodium chloride injection passed the consistency evaluation [7] - Shapuaisi received approval for a supplemental application for levofloxacin eye drops [9] - Tianyu Biological reported April sales revenue of 59.32 million yuan from pig sales [10] Group 4 - *ST Weihai was pre-awarded a project worth 108 million yuan [12] - Luoniushan reported April sales revenue of 125 million yuan from pig sales, a year-on-year increase of 12.72% [13] - Minhe Co. reported April sales revenue of 68.30 million yuan from chick sales, a year-on-year increase of 0.51% [14] Group 5 - Double Ring Technology's application for a specific stock issuance was approved by the Shenzhen Stock Exchange [15] - Hualu Hengsheng plans to repurchase shares worth between 200 million and 300 million yuan [16] - Baolong Technology plans to repurchase shares worth between 100 million and 200 million yuan [17] Group 6 - Huasheng Technology's subsidiary plans to sell shares of a company for 200 million yuan [24] - *ST Gengxing's controlling shareholder plans to increase holdings worth between 30 million and 60 million yuan [25] - Ruihuatai's shareholder plans to reduce holdings by up to 1% of the company's shares [26] Group 7 - Foton Motor reported April commercial vehicle sales of 54,816 units, a year-on-year increase of 21.63% [20] - China Merchants Bank plans to invest 15 billion yuan to establish a financial asset investment company [22] - Jinchengxin plans to invest approximately 231 million USD in the Alacran copper-gold-silver mine project [23] Group 8 - Zhongji United's controlling shareholder plans to reduce holdings by up to 2% of the company's shares [30] - Ningbo Huaxiang signed a strategic cooperation agreement to strengthen collaboration in various areas [31] - SMIC reported a net profit of 1.356 billion yuan for Q1 2025, a year-on-year increase of 166.5% [32] Group 9 - FAW Fuwi received a project notification to develop seat products for a luxury brand, with a total sales amount expected to be 1.39 billion yuan [33] - Huakang Clean won a bid for a purification project worth 64.425 million yuan [34] - Lihua Co. reported April sales revenue of 1.125 billion yuan from chicken sales [35]

关于召开 2024年度网上业绩说明会的公告 重要内容提示： 证券代码：000790 证券简称：华神科技 公告编号：2025-018 成都华神科技集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二、参加人员 公司董事长、总裁黄明良先生，独立董事毛道维先生，独立董事陈旭东先 生，独立董事朱超溪女士，副总裁兼财务总监李俊先生，董事会秘书宁潞宏先 生（如遇特殊情况，出席人员将酌情调整）。 三、投资者参加方式 投资者可于2025年05月15日（星期四）15:00-16:30通过网址https://eseb.cn/1 o6IXOaVoCk或使用微信扫描下方小程序码即可进入参与互动交流。投资者可于 2025年05月15日前进行会前提问，公司将通过本次业绩说明会，在信息披露允 许范围内就投资者普遍关注的问题进行回答。 成都华神科技集团股份有限公司（简称"公司"）已于 2025 年 4 月 29 日在 巨潮资讯网（www.cninfo.com.cn）披露了《2024 年年度报告》及其摘要。为方 便广大投资者更加全面深入地了解公司发展战略、经营业绩等情况，公司定 ...

Core Insights - The behavior of margin traders has attracted significant market attention, with investors hoping to capture investment opportunities from their activities [1] Group 1: Margin Trading Data - On May 8, a total of 3,663 stocks received margin buying funds, with the top three stocks being Xinyi Technology (¥1.425 billion), Zhongji Xuchuang (¥1.053 billion), and Shenghong Technology (¥807 million) [1] - The table lists stocks with the highest margin buying amounts, including Tiancheng Technology (¥15.75 million), Xingqiu Graphite (¥8.83 million), and Lianyu Co. (¥15.27 million), showing their respective transaction amounts and margin buying ratios [1] - Margin buying accounted for significant percentages of total transaction amounts for various stocks, with Tiancheng Technology at 28.65%, Xingqiu Graphite at 28.51%, and Lianyu Co. at 28.15% [1] Group 2: Stock Performance - The price changes of stocks with high margin buying varied, with some stocks experiencing gains, such as Tiancheng Technology (1.47%) and Xingqiu Graphite (2.39%), while others like Fuliwang saw a decline (-3.29%) [1][2] - The data indicates that margin buying can correlate with stock performance, as seen in the fluctuations of the stocks listed [1][2]

Investment Announcements - Jinchengxin plans to invest approximately $231 million in the development of the Alacran copper-gold-silver mine project, aiming to acquire a 55% stake in CMH Colombia S.A.S. after the acquisition [3] - China Merchants Bank intends to invest 15 billion yuan to establish a wholly-owned financial asset investment company, enhancing its integrated financial services capabilities [5][6] Performance Reports - Huahong Semiconductor reported Q1 2025 revenue of 3.913 billion yuan, an 18.66% year-on-year increase, but net profit decreased by 89.73% to 22.76 million yuan due to uncertainties in the semiconductor industry [7] - King Long Motor's April bus sales were 3,611 units, a 3.91% year-on-year decrease, while production was 4,361 units, down 5.79% year-on-year [8] - Zhengbang Technology reported April sales of 609,800 pigs, with revenue of 738 million yuan, a 174.29% year-on-year increase, attributed to orderly resumption of production [9] - Sunac China achieved a contract sales amount of approximately 1.1 billion yuan in April, with a cumulative total of 11.2 billion yuan by the end of April [10] Major Contracts - Pinggao Electric won contracts totaling approximately 1.751 billion yuan from the State Grid, representing 14.12% of its 2024 revenue [13] - State Grid Information Technology's subsidiaries secured contracts worth 477 million yuan, positively impacting future operating performance [14] - Dongfang Iron Tower won contracts worth about 100 million yuan from the State Grid, accounting for 2.39% of its 2024 revenue [15] - Jiaojian Co. won a construction project worth approximately 704 million yuan, representing 8.43% of its 2024 revenue [16] Shareholding Changes - Ruihua Tai's shareholder plans to reduce holdings by up to 1% of the company's shares [17][18] - *ST Gengxing's controlling shareholder intends to increase holdings between 30 million and 60 million yuan [19] - Lexin Technology's shareholder plans to reduce holdings by up to 1.2032% of the company's shares [20] Share Buybacks - Sichuan Meifeng plans to repurchase shares worth 50 million to 70 million yuan, with a maximum buyback price of 10.07 yuan per share [21]